The association between aortic stenosis and some degree of mitral stenosis (MS) is around 10% (depending on the series), and it is related with negative outcomes. In high-risk and inoperable patients who underwent TAVR, that association and its significance have not been studied yet. The study analyzed data from the Society of Thoracic Surgeons/American...
State of the art : Treatment of Mitral Stenosis
By: Saibal Kar
Post-MitraClip Mitral Valve Stenosis: Bad Prognosis
The EVEREST II trial has shown the MitraClip has similar mortality rate to that of surgery and, on the other hand, we are well aware that residual mitral regurgitation (MR) is associated with a strong negative impact. However, research has shown little about transvalvular gradient after MitraClip and what it entails. 268 patients receiving MitraClip were...
Bad prognosis for post-MitraClip mitral valve stenosis: how do we proceed?
Courtesy of Dr. Carlos Fava The EVEREST II trial showed the MitraClip had similar mortality rate to that of surgery but, even though residual mitral valve regurgitation (MR) is associated to a strong negative impact, little is known about post MitraClip increased transvalvular gradient and its implication. 268 patients undergoing MC implantation were analyzed....
Estenosis Mitral: Indicaciones y Técnicas del Tratamiento Endovascular. Resultados Inmediatos e Alejados
Mangione, José Armando2014-04-22
TAVR in the Different Types of Aortic Stenosis
Aortic stenosis (AS) is classified according to gradient into high flow and high gradient (D1), low flow-low gradient with reduced ejection fraction (D2), and paradoxical low flow-low gradient with conserved ejection fraction (D3). D3 AS is characterized by ≥50% ejection fraction, but with systolic volume index ≤35 ml/min. Post TAVR evolution of D2 and D3...
Promising Results of Transcatheter Mitral Valve Replacement in Bioprosthesis Failure
Failure of a mitral bioprosthesis always poses a challenge regarding decision-making, especially when dealing with elderly patients with multiple risk factors. The scenario is worsened by the high risk associated with a new sternotomy and the significant impact of undergoing new surgery. Transcatheter mitral valve-in-valve (TMViV) replacement is emerging as a valid strategy in the...
Untreated Aortic Stenosis: Associated Mortality and a Call to Attention
The progression of aortic stenosis has been extensively studied and is well-known. As observed, in its advanced stages, this condition entails high morbidity and a marked decrease in survival. Both North American and European guidelines recommend treatment when faced with severe valve disease. However, true severity can be difficult to determine due to discordant data,...
Moderate Aortic Stenosis: We Should Start Assessing It More Thoroughly
Moderate aortic stenosis (MAS) encompasses a broader spectrum than severe aortic stenosis. However, its progression has not yet been fully elucidated. While there are reports suggesting that this condition is not as benign as initially believed, there is a need to consider early interventions in certain instances. Researchers conducted an analysis from January 2016 to...
Transcatheter Mitral Valve Replacement vs. Medical Therapy
Mitral valve regurgitation (MR) is a common cause behind heart failure and is associated to hospitalization for heart failure and higher mortality. Transcatheter edge-to-edge repair (TEER), together with guideline-directed medical therapy (GDMT) has been shown beneficial in high risk patients, according to the COAPT study. However, there is a significant group of patients that make...